An official website of the United States government
BACKGROUND Timely interventions, such as antibiotics and intravenous fluids, have been associated with reduced mortality in patients with sepsis. Artificial intelligence (AI) models that accurately predict risk of sepsis onset could speed the delivery of these interventions. Although sepsis models generally aim to predict its onset, clinicians might recognize and treat sepsis before the sepsis definition is met. Predictions occurring after sepsis is clinically recognized (i.e., after treatment begins) may be of limited utility. Researchers have not previously investigated the accuracy of sepsis risk predictions that are made before treatment begins. Thus, we evaluate the discriminative performance of AI sepsis predictions made throughout a hospitalization relative to the time of treatment. METHODS We used a large retrospective inpatient cohort from the University of Michigan’s academic medical center (2018–2020) to evaluate the Epic sepsis model (ESM). The ability of the model to predict sepsis, both before sepsis criteria are met and before indications of treatment plans for sepsis, was evaluated in terms of the area under the receiver operating characteristic curve (AUROC). Indicators of a treatment plan were identified through electronic data capture and included the receipt of antibiotics, fluids, blood culture, and/or lactate measurement. The definition of sepsis was a composite of the Centers for Disease Control and Prevention’s surveillance criteria and the severe sepsis and septic shock management bundle definition. RESULTS The study included 77,582 hospitalizations. Sepsis occurred in 3766 hospitalizations (4.9%). ESM achieved an AUROC of 0.62 (95% confidence interval [CI], 0.61 to 0.63) when including predictions before sepsis criteria were met and in some cases, after clinical recognition. When excluding predictions after clinical recognition, the AUROC dropped to 0.47 (95% CI, 0.46 to 0.48). CONCLUSIONS We evaluate a sepsis risk prediction model to measure its ability to predict sepsis before clinical recognition. Our work has important implications for future work in model development and evaluation, with the goal of maximizing the clinical utility of these models. (Funded by Cisco Research and others.)
more »
« less
Machine-learning-enabled prognostic models for sepsis
Background and Objectives: Sepsis is a leading cause of mortality in intensive care units (ICUs). The development of a robust prognostic model utilizing patients’ clinical data could significantly enhance clinicians’ ability to make informed treatment decisions, potentially improving outcomes for septic patients. This study aims to create a novel machine-learning framework for constructing prognostic tools capable of predicting patient survival or mortality outcome. Methods: A novel dataset is created using concatenated triples of static data, temporal data, and clinical outcomes to expand data size. This structured input trains five machine learning classifiers (KNN, Logistic Regression, SVM, RF, and XGBoost) with advanced feature engineering. Models are evaluated on an independent cohort using AUROC and a new metric, 𝛾, which incorporates the F1 score, to assess discriminative power and generalizability. Results: We developed five prognostic models using the concatenated triple dataset with 10 dynamic features from patient medical records. Our analysis shows that the Extreme Gradient Boosting (XGBoost) model (AUROC = 0.777, F1 score = 0.694) and the Random Forest (RF) model (AUROC = 0.769, F1 score = 0.647), when paired with an ensemble under-sampling strategy, outperform other models. The RF model improves AUROC by 6.66% and reduces overfitting by 54.96%, while the XGBoost model shows a 0.52% increase in AUROC and a 77.72% reduction in overfitting. These results highlight our framework’s ability to enhance predictive accuracy and generalizability, particularly in sepsis prognosis. Conclusion: This study presents a novel modeling framework for predicting treatment outcomes in septic patients, designed for small, imbalanced, and high-dimensional datasets. By using temporal feature encoding, advanced sampling, and dimension reduction techniques, our approach enhances standard classifier performance. The resulting models show improved accuracy with limited data, offering valuable prognostic tools for sepsis management. This framework demonstrates the potential of machine learning in small medical datasets.
more »
« less
- Award ID(s):
- 1954532
- PAR ID:
- 10556776
- Publisher / Repository:
- Elsevier B.V.
- Date Published:
- Journal Name:
- Intelligencebased medicine
- Edition / Version:
- 10
- ISSN:
- 2666-5212
- Format(s):
- Medium: X
- Sponsoring Org:
- National Science Foundation
More Like this
-
-
BackgroundMetastatic cancer remains one of the leading causes of cancer-related mortality worldwide. Yet, the prediction of survivability in this population remains limited by heterogeneous clinical presentations and high-dimensional molecular features. Advances in machine learning (ML) provide an opportunity to integrate diverse patient- and tumor-level factors into explainable predictive ML models. Leveraging large real-world datasets and modern ML techniques can enable improved risk stratification and precision oncology. ObjectiveThis study aimed to develop and interpret ML models for predicting overall survival in patients with metastatic cancer using the Memorial Sloan Kettering-Metastatic (MSK-MET) dataset and to identify key prognostic biomarkers through explainable artificial intelligence techniques. MethodsWe performed a retrospective analysis of the MSK-MET cohort, comprising 25,775 patients across 27 tumor types. After data cleaning and balancing, 20,338 patients were included. Overall survival was defined as deceased versus living at last follow-up. Five classifiers (extreme gradient boosting [XGBoost], logistic regression, random forest, decision tree, and naive Bayes) were trained using an 80/20 stratified split and optimized via grid search with 5-fold cross-validation. Model performance was assessed using accuracy, area under the curve (AUC), precision, recall, and F1-score. Model explainability was achieved using Shapley additive explanations (SHAP). Survival analyses included Kaplan-Meier estimates, Cox proportional hazards models, and an XGBoost-Cox model for time-to-event prediction. The positive predictive value and negative predictive value were calculated at the Youden index–optimal threshold. ResultsXGBoost achieved the highest performance (accuracy=0.74; AUC=0.82), outperforming other classifiers. In survival analyses, the XGBoost-Cox model with a concordance index (C-index) of 0.70 exceeded the traditional Cox model (C-index=0.66). SHAP analysis and Cox models consistently identified metastatic site count, tumor mutational burden, fraction of genome altered, and the presence of distant liver and bone metastases as among the strongest prognostic factors, a pattern that held at both the pan-cancer level and recurrently across cancer-specific models. At the cancer-specific level, performance varied; prostate cancer achieved the highest predictive accuracy (AUC=0.88), while pancreatic cancer was notably more challenging (AUC=0.68). Kaplan-Meier analyses demonstrated marked survival separation between patients with and without metastases (80-month survival: approximately 0.80 vs 0.30). At the Youden-optimal threshold, positive predictive value and negative predictive value were approximately 70% and 80%, respectively, supporting clinical use for risk stratification. ConclusionsExplainable ML models, particularly XGBoost combined with SHAP, can strongly predict survivability in metastatic cancers while highlighting clinically meaningful features. These findings support the use of ML-based tools for patient counseling, treatment planning, and integration into precision oncology workflows. Future work should include external validation on independent cohorts, integration with electronic health records via Fast Healthcare Interoperability Resources–based dashboards, and prospective clinician-in-the-loop evaluation to assess real-world use.more » « less
-
Guillot, Gilles (Ed.)Diagnostic and prognostic models are increasingly important in medicine and inform many clinical decisions. Recently, machine learning approaches have shown improvement over conventional modeling techniques by better capturing complex interactions between patient covariates in a data-driven manner. However, the use of machine learning introduces technical and practical challenges that have thus far restricted widespread adoption of such techniques in clinical settings. To address these challenges and empower healthcare professionals, we present an open-source machine learning framework, AutoPrognosis 2.0, to facilitate the development of diagnostic and prognostic models. AutoPrognosis leverages state-of-the-art advances in automated machine learning to develop optimized machine learning pipelines, incorporates model explainability tools, and enables deployment of clinical demonstrators,withoutrequiring significant technical expertise. To demonstrate AutoPrognosis 2.0, we provide an illustrative application where we construct a prognostic risk score for diabetes using the UK Biobank, a prospective study of 502,467 individuals. The models produced by our automated framework achieve greater discrimination for diabetes than expert clinical risk scores. We have implemented our risk score as a web-based decision support tool, which can be publicly accessed by patients and clinicians. By open-sourcing our framework as a tool for the community, we aim to provide clinicians and other medical practitioners with an accessible resource to develop new risk scores, personalized diagnostics, and prognostics using machine learning techniques. Software:https://github.com/vanderschaarlab/AutoPrognosismore » « less
-
Abstract Sepsis is responsible for the highest economic and mortality burden in critical care settings around the world, prompting the World Health Organization in 2018 to designate it as a global health priority. Despite its high universal prevalence and mortality rate, a disproportionately low amount of sponsored research funding is directed toward diagnosis and treatment of sepsis, when early treatment has been shown to significantly improve survival. Additionally, current technologies and methods are inadequate to provide an accurate and timely diagnosis of septic patients in multiple clinical environments. For improved patient outcomes, a comprehensive immunological evaluation is critical which is comprised of both traditional testing and quantifying recently proposed biomarkers for sepsis. There is an urgent need to develop novel point‐of‐care, low‐cost systems which can accurately stratify patients. These point‐of‐critical‐care sensors should adopt a multiplexed approach utilizing multimodal sensing for heterogenous biomarker detection. For effective multiplexing, the sensors must satisfy criteria including rapid sample to result delivery, low sample volumes for clinical sample sparring, and reduced costs per test. A compendium of currently developed multiplexed micro and nano (M/N)‐based diagnostic technologies for potential applications toward sepsis are presented. We have also explored the various biomarkers targeted for sepsis including immune cell morphology changes, circulating proteins, small molecules, and presence of infectious pathogens. An overview of different M/N detection mechanisms are also provided, along with recent advances in related nanotechnologies which have shown improved patient outcomes and perspectives on what future successful technologies may encompass. This article is categorized under:Diagnostic Tools > Biosensingmore » « less
-
Abstract ObjectivesTo quantify differences between (1) stratifying patients by predicted disease onset risk alone and (2) stratifying by predicted disease onset risk and severity of downstream outcomes. We perform a case study of predicting sepsis. Materials and MethodsWe performed a retrospective analysis using observational data from Michigan Medicine at the University of Michigan (U-M) between 2016 and 2020 and the Beth Israel Deaconess Medical Center (BIDMC) between 2008 and 2012. We measured the correlation between the estimated sepsis risk and the estimated effect of sepsis on mortality using Spearman’s correlation. We compared patients stratified by sepsis risk with patients stratified by sepsis risk and effect of sepsis on mortality. ResultsThe U-M and BIDMC cohorts included 7282 and 5942 ICU visits; 7.9% and 8.1% developed sepsis, respectively. Among visits with sepsis, 21.9% and 26.3% experienced mortality at U-M and BIDMC. The effect of sepsis on mortality was weakly correlated with sepsis risk (U-M: 0.35 [95% CI: 0.33-0.37], BIDMC: 0.31 [95% CI: 0.28-0.34]). High-risk patients identified by both stratification approaches overlapped by 66.8% and 52.8% at U-M and BIDMC, respectively. Accounting for risk of mortality identified an older population (U-M: age = 66.0 [interquartile range—IQR: 55.0-74.0] vs age = 63.0 [IQR: 51.0-72.0], BIDMC: age = 74.0 [IQR: 61.0-83.0] vs age = 68.0 [IQR: 59.0-78.0]). DiscussionPredictive models that guide selective interventions ignore the effect of disease on downstream outcomes. Reformulating patient stratification to account for the estimated effect of disease on downstream outcomes identifies a different population compared to stratification on disease risk alone. ConclusionModels that predict the risk of disease and ignore the effects of disease on downstream outcomes could be suboptimal for stratification.more » « less
- Free Publicly Accessible Full Text
-
Accepted Manuscript1.0
- Journal Article:
- The DOI is not currently available.
